234 related articles for article (PubMed ID: 28878573)
41. The Cost-Effectiveness of Quadrivalent Human Papillomavirus Vaccination in Indonesia.
Kosen S; Andrijono A; Ocviyanti D; Indriatmi W
Asian Pac J Cancer Prev; 2017 Jul; 18(7):2011-2017. PubMed ID: 28749644
[TBL] [Abstract][Full Text] [Related]
42. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK.
Dasbach EJ; Insinga RP; Elbasha EH
BJOG; 2008 Jul; 115(8):947-56. PubMed ID: 18503574
[TBL] [Abstract][Full Text] [Related]
43. Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States.
Brisson M; Laprise JF; Chesson HW; Drolet M; Malagón T; Boily MC; Markowitz LE
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26438574
[TBL] [Abstract][Full Text] [Related]
44. Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys.
Burger EA; Sy S; Nygård M; Kristiansen IS; Kim JJ
PLoS One; 2014; 9(3):e89974. PubMed ID: 24651645
[TBL] [Abstract][Full Text] [Related]
45. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.
Dasbach EJ; Insinga RP; Yang YC; Pwu RF; Lac C; Elbasha EH
Asian Pac J Cancer Prev; 2008; 9(3):459-66. PubMed ID: 18990021
[TBL] [Abstract][Full Text] [Related]
46. Cost-effectiveness of human papillomavirus vaccination in girls living in Latin American countries: A systematic review and meta-analysis.
Tejada RA; Malagón T; Franco EL
Vaccine; 2022 Apr; 40(19):2667-2678. PubMed ID: 35370017
[TBL] [Abstract][Full Text] [Related]
47. A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme.
Dee A; Howell F
Eur J Public Health; 2010 Apr; 20(2):213-9. PubMed ID: 19864366
[TBL] [Abstract][Full Text] [Related]
48. Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France.
Majed L; Bresse X; El Mouaddin N; Schmidt A; Daniels VJ; Pavelyev A; Levy-Bachelot L; Elbasha E
Vaccine; 2021 Jan; 39(2):438-446. PubMed ID: 33261895
[TBL] [Abstract][Full Text] [Related]
49. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model.
Jit M; Chapman R; Hughes O; Choi YH
BMJ; 2011 Sep; 343():d5775. PubMed ID: 21951758
[TBL] [Abstract][Full Text] [Related]
50. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.
Kulasingam S; Connelly L; Conway E; Hocking JS; Myers E; Regan DG; Roder D; Ross J; Wain G
Sex Health; 2007 Sep; 4(3):165-75. PubMed ID: 17931529
[TBL] [Abstract][Full Text] [Related]
51. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis.
Kulasingam SL; Benard S; Barnabas RV; Largeron N; Myers ER
Cost Eff Resour Alloc; 2008 Feb; 6():4. PubMed ID: 18279515
[TBL] [Abstract][Full Text] [Related]
52. The epidemiologic and economic impact of a quadrivalent human papillomavirus vaccine in Thailand.
Termrungruanglert W; Khemapech N; Vasuratna A; Havanond P; Deebukkham P; Kulkarni AS; Pavelyev A
PLoS One; 2021; 16(2):e0245894. PubMed ID: 33571186
[TBL] [Abstract][Full Text] [Related]
53. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.
Capri S; Gasparini R; Panatto D; Demarteau N
Gynecol Oncol; 2011 Jun; 121(3):514-21. PubMed ID: 21334734
[TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness of HPV vaccination in Belize.
Walwyn L; Janusz CB; Clark AD; Prieto E; Waight E; Largaespada N
Vaccine; 2015 May; 33 Suppl 1():A174-81. PubMed ID: 25919158
[TBL] [Abstract][Full Text] [Related]
55. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.
Demarteau N; Tang CH; Chen HC; Chen CJ; Van Kriekinge G
Value Health; 2012; 15(5):622-31. PubMed ID: 22867770
[TBL] [Abstract][Full Text] [Related]
56. Revisiting the cost-effectiveness of universal HPV-vaccination in Denmark accounting for all potentially vaccine preventable HPV-related diseases in males and females.
Olsen J; Jørgensen TR
Cost Eff Resour Alloc; 2015; 13():4. PubMed ID: 25694771
[TBL] [Abstract][Full Text] [Related]
57. Cost-effectiveness analysis of single-dose or 2-dose of bivalent, quadrivalent, or nonavalent HPV vaccine in a low/middle-income country setting.
Termrungruanglert W; Khemapech N; Vasuratna A; Havanond P; Tantitamit T
J Gynecol Oncol; 2024 Apr; ():. PubMed ID: 38670561
[TBL] [Abstract][Full Text] [Related]
58. Model for assessing human papillomavirus vaccination strategies.
Elbasha EH; Dasbach EJ; Insinga RP
Emerg Infect Dis; 2007 Jan; 13(1):28-41. PubMed ID: 17370513
[TBL] [Abstract][Full Text] [Related]
59. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model.
Jit M; Brisson M; Laprise JF; Choi YH
BMJ; 2015 Jan; 350():g7584. PubMed ID: 25567037
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
